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ABSTRACT: The recognition of the dopaminergic properties of some ergot derivatives has initiated new therapeutical approaches in 
endocrinology as well as in neurology. The pharmacological characterization of the different ergot derivatives during the last decade 
has largely improved our understanding of central dopaminergic systems. Their development has yielded valuable information on the 
pharmacology of dopamine receptors involved in the regulatory mechanisms of prolactin secretion and in striatal functions. 
The clinical application of such new neurobiological concepts has underlined the therapeutical interest of such compounds either 
in the control of prolactin-dependent endocrine disorders or in the treatment of parkinsonism. Owing to their pharmacological 
profiles, dopaminergic agonists represent a valuable clinical option especially in the management of Parkinson's disease in view of 
the problems arising from chronic L-Dopa treatment. 
RESUME: L'identification des proprietes dopaminergiques de certains derives de l'ergot a permis d'envisager de nouvelles 
approches therapeutiques tant en endocrinologie qu'en neurologic Au cours des dix dernieres annees, la caracterisation de leurs 
differents profils pharmacologiques, souvent complexes, a largement contribue au developpement de nos connaissances sur les 
meCanismes dopaminergiques qui regissent la regulation de la secretion de prolactine ainsi que la regulation striatale des activites 
motrices. De plus, le developpement de derives ergotes dopaminomimetiques a permis l'identification des differents sites recepteurs 
de la dopamine. 
L'application clinique de ces nouveaux concepts neurobiologiques a revele l'interet porte a ces substances notamment dans le 
controle des desordres endocriniens prolactino-dependants ainsi que dans le traitement de la maladie de Parkinson. De par leur 
pharmacologic, les agonistes dopaminergiques constituent, notamment dans le cadre de la maladie de Parkinson, une alternative 
clinique non negligeable aux problemes lies au traitement chronique par la L-Dopa. 
Can. J. Neurol. Sci. 1984; 11:118-123 
"Until we are better informed respecting 
the nature of this disease, the employment 
of internal medicines is scarcely warrantable". 
J. PARKINSON, 1817. 
Twenty years ago, pharmacologists were preoccupied with 
the characterization of the a-adrenergic and serotoninergic 
properties of ergot derivatives as potentially beneficial in the 
treatment of migraine. 
However, for many years, interactions with reproductive 
functions have been reported to result from the use of certain 
ergot alkaloids. Contamination of sow-feed with ergot ofClaviceps 
sp. (Shone etal., 1959; Loveless, 1967; Mantle, 1968a) or Sphacelia 
sp. (Mantle, 1968b) was responsible for endemic agalactia in 
sows. Despite these observations, the inhibitory effect of pro-
lactin secretion induced by ergot alkaloids and their derivatives 
was first suggested by Shelesnyak (1954). This original report 
underlined the inhibitory effects upon deciduoma formation 
and ovum implantation in the rat uterus induced by ergotoxine. 
This effect, reversed by injections of progesterone or prolactin 
(Shelesnyak, 1958), was indicative of a direct (pituitary) or 
indirect (hypothalamus) inhibition of prolactin secretion induced 
by ergotoxine. 
This hypothesis was confirmed by Zeilmaker and Carlsen 
(1962). At that time, ergot chemists and pharmacologists in our 
laboratories began their search for an ergot alkaloid or a deriva-
tive which would selectively inhibit prolactin secretion as its 
main action. 
Among various compounds tested, 2-bromo-a-ergocryptine 
methanesulfonate (bromocriptine) was the most promising struc-
ture exhibiting such a specific action upon prolactin secretion. 
Bromocriptine (for synthesis and activity see e.g. Schneider et 
al., 1977), was chosen to be developed for testing in human in 
1967. However the existence of human prolactin, as a separate 
pituitary hormone, was negated by most endocrinologists 
(Geschwind, 1972) except Pasteels (1973). Moreover, there 
was no receptor concept in support of a possible inhibition of 
prolactin secretion, adrenoceptors and serotonin receptors not 
being involved. 
The clinical situation was dramatically changed by the recog-
nition of human prolactin (h Prl) as a discrete hormonal entity 
(Frantz et al., 1970; Hwang et al., 1971; Lewis et al., 1971; 
Loewenstein, 1971; Turkington, 1971) and the concomitant 
development of a suitable radio-immunoassay for h Prl (Hwang, 
1971). 
As the prolactin concept was developed, bromocriptine was 
intensively investigated to improve our understanding of its 
action profile. Among the various investigations performed, 
the interaction of bromocriptine and ergocornine with hypo-
thalamic catecholaminergic neurons (Fuxe et al., 1970; Hoekfelt 
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et al., 1972) provided an essential clue in ergot pharmacology 
by demonstrating their ability to reduce dopamine (DA) turn-
over in hypothalamic and neostriatal dopaminergic neurons. 
Such central dopaminomimetic properties were confirmed by 
Corrodi et al. (1973), Myamoto et al. (1974) and Johnson et al. 
(1976). Hence the ability to stimulate DA receptors was recog-
nized for ergot compounds and the clinical relevance of this 
property was soon demonstrated in patients with Parkinson's 
disease (Calne et al., 1974a and b). 
However, the nature of the regulation of prolactin secretion 
was still unknown. The link between DA receptor stimulation 
and inhibition of prolactin secretion induced by bromocriptine 
was clearly demonstrated only somewhat later (Flueckiger et 
al., 1976; MacLeod, 1976). 
This brief review of the most recent aspects of the develop-
ment of the pharmacology of ergot derivatives underlines the 
broad spectrum of their potential activities resulting from their 
ability to interact with different receptor systems. 
Dopaminomimetic Agents and Parkinson's Disease 
The clinical use of dopaminergic compounds in the treatment 
of Parkinson's disease was suggested by Fuxe et al. (1970) and 
established by Calne et al. (1974a). However, ergot derivatives 
were proposed a century ago in the treatment of paralysis 
agitans, on the basis of their parasympatholytic properties. 
Charcot (1892) reported the lack of beneficial effects of ergot 
alkaloids as well as for atropabelladona in parkinsonian patients. 
At that time, only low-molecular-weight ergot alkaloids were 
used in such clinical conditions. In the early 1940's, it was 
proposed mainly in Germany, to use a dry extract of bovine 
striatum for parkinsonism. The drug, called Striaphorin, was 
produced for some years without any significant success. We 
know now that if the active principle of such a preparation was 
dopamine, this could never cross the blood-brain barrier to 
reach its target. 
The first real attempts to use dopaminergic agents in the 
treatment of Parkinson's disease were made when the dopa-
mine theory of Parkinson's disease was verified (Ehringer and 
Hornykiewicz 1960, Barbeau, 1960). Apomorphine was a prime 
clinical candidate after the identification of its pharmacologic 
similarities with dopamine (Ernst, 1967; Ungerstedt etal., 1969). 
Despite its beneficial effect in early clinical trial (Cotzias et 
al., 1970, Castaigne etal., 1977), the use of apomorphine appears 
to be limited clinically owing to its nephrotoxicity (Papavasiliou 
et al., 1978), strong emetic action, rapid metabolism and lack of 
oral activity (Castaigne etal., 1971;Schwab, 1951). Some deriva-
tives of apomorphine (n-propyl-norapomorphine) were pro-
posed (Cotzias et al., 1976; Papavasiliou et al., 1978). 
The profile of apomorphine-as a dopaminergic stimulant and 
its beneficial effects upon parkinsonian symptoms had encour-
aged the search for other dopaminomimetic agents. A dopa-
minergic profile was proved for different ergoline derivatives, 
including bromocriptine (Corrodi etal., 1973; Fuxe etal., 1978), 
lergotrile (Fuller and Perry, 1978; Wong and Bymaster, 1978), 
pergolide (Fuller et al., 1979; Wong et al., 1979) and lisuride 
(Graf et al., 1976), indicating their possible use for the manage-
ment of parkinsonism. 
More recently a number of other ergot compounds have also 
been found to interact with DA receptors within the striatum, 
e.g. CH 29-717, CQ 32-084 and CU 32-085 (Flueckiger et al., 
1979). 
For many of these dopaminomimetic agents, the starting 
point for chemists was the ergoline skeleton of ergot leading to 
three ergot families: clavines, lysergic acid amides and 8 a-amino-
Dopaminergic compounds derived from ergolene structure 
H-. ^ C H , - R ' 
Clavines 
Methergolme 
Lergotrile 
Pergolide 
CF 25-397 
CM 29-712(1) 
HN ^ 6-alkyl-9-ergolene 
H-. ^CONH-R" 
Lysergic acid amides 
R" = aliphatic 
Methysergide 
M e t h yl -e rgomet ruie 
Ergometrine 
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R" suDsMuted cyclol 
(ergopeptmes) 
Bromocriptine 
D i riy d ro -a-ergo kry p! m o 
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Lisuride 
CH 29-717 
CQ 32-0S4 
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2) New non-propriety names co-dergocrine (BAN), ergolo'd mesylate (USAN) 
3) New non-propriety name mesulergine 
Figure 1 — Chemical structures of the different families of ergot compounds 
exhibiting dopaminomimetic properties, (from Vigouret et al., 1978; 
Flueckiger etal., 1979, 1983b). 
Table 1: Comparison of central dopaminergic properties of various ergot compound 
Ergopeptine = Bromocriptine 
Clavines = Lergotrile 
Pergolide 
CF 25-397 
CM 29-712 
Amino-Ergoline = Lisuride 
CH 29-717 
CQ 32-084 
Mesulergine 
Dopamine 
Apomorphine 
(1) 
Prl tJRat(2hr) 
ID50 (ix/kg s.c.) 
8 
16 
0.44 
720 
16 
3.9 
0.89 
5 
10 
1800 
(2) 
Turning Behaviour 
Ungerstedt Rat 
MED (ixg/kg) 
100 s.c. 
100 s.c. 
10 s.c. 
300 s.c. 
50 i.p. 
10 s.c. 
50 i.p. 
10 s.c. 
300 s.c. 
10 
s 
(3) 
Ach Release 
Rat Striatum 
ICS0 (nM) 
5.0 
3.2 
40.0 
Antag. 
5.0 
2.5 
1580 
? 
25.0 
(4) 
DA Release 
Rat Striatum 
Ag. (nM) 
0 
Ag. (M-M) 
Antag. 
Ag. (?) 
Ag. (nM) 
(5) (6) 
DA • AC Calf Caudatum 
Rat Striatum 3H-DA/3H-Spiro 
Er pD2/pKi IC50 (nM) 
0 
0 
30 
34 
34 
0 
0 
32 
0 
100 
69 
6.0 
6.6 
5.4 
5.8 
6.3 
6.3 
6.4 
6.2 
0 
0 
0 
7.0 
<5 
0 
6.3 
0 
0 
84 
210 
120 
1400 
13 
120 
25 
140 
Results from (1) Flueckiger et al. (1979); (2) Vigouret et al. (1978); (3)-(5) Markstein (1981) and unpublished; (6) Closse et al. (1980). 
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Table 2: Comparison of neurochemical properties: bromocriptine and mesulergine (from Markstein, unpublished) 
(1) (2) (3) 
DA Receptors 5HT-Receptors Adrenoreceptors 
DA-AC( + ) DA-AC(-) (5 HT2) al + a2 
(Dl) (D2) 
Bromocriptine - + + + — — 
Mesulergine (CU 32-085) - + + + + + 
(Antagonism) 
Table 3: Comparison of clinical profiles of ergot derivatives in Parkinson's disease (from Rinne, 1983 with permission) 
Therapeutic Response Adverse Reactions 
Antiparkinsonian Mood Nausea - Cardiovascular Hallucinations 
Compound efficacy elevation vomiting activity* Sedation + confusion Dyskinesia 
Bromocriptine + + + + + + + + + + 
CM 29-712 + - + + + + + + + ± 
CQ 32-084 + + + + + + + + + + + 
CU 32-085 + + + + + ± + + + 
*Decrease of blood pressure and the occurrence of postural hypotension. 
Effect of mesulergine on DOPAC in rat striatum 
9 n (Enz et al., 1983) 
15- / 
pmol/mg
 1Q_ / 
striatum / „<2v 
u - l 1 1 1 1 1 1 
0 2 4 6 
Time after applic. (hours) 
• »3.2mg/kg s.c. •-—•10mg/kgp.o. •-—•3.2mg/kg i.p. 
Figure 2 — Effect of Mesulergine on DOPAC level in rat striatum, (from Enz 
et al., 1983 with permission). 
ergolines (Fig. 1). The pharmacological profile of these deriva-
tives is quite different in terms of structure-activity relationships 
as agonists and/or antagonists upon a-adrenoreceptors, serotonine 
receptors and DA receptors. The pharmacology of ergot alka-
loids and their derivatives has been extensively reviewed recently 
(BerdeandSchild, 1978; Clark etal., 1978;Fuxe, 1979;Thorner 
et al., 1980; Flueckiger et al., 1981; Lataste, 1981; Flueckiger 
and Markstein, 1982;Flueckiger, 1983a; Flueckiger etal., 1983b; 
Tranetal . , 1983;Calne, 1983; Fuxe etal. , 1983). In Table 1 are 
summarized the available pharmacological data of a number of 
ergot compounds of proven activity in parkinsonism, com-
pared with apomorphine and dopamine. 
Specific Aspects of Ergot Pharmacology 
Among the various pharmacological aspects of ergot deriva-
tives, I would like to concentrate my review upon some pharma-
codynamic properties which could be relevant for their thera-
peutic use. When central dopaminergic activities are compared, 
quite different overall potency profiles can be characterized. 
Compared with bromocriptine, mesulergine (CU 32-085) as a 
8-a-amino-ergoline derivative has a different potency in in vivo 
models (Table 1). 
The distinctive pharmacological profiles obtained from ergot 
derivatives include not only their specific interactions with the 
different subtypes of DA receptors but also their possible inter-
ferences with other transmitter receptors including adrenoceptors 
and serotonine receptors (Table 2). 
Such a complex pharmacology suggests that these compounds 
may induce different clinical responses in the management of 
parkinsonian symptoms. However, the clinical results so far 
obtained with these compounds (Rinne, 1983) do not yet allow 
correlation of their efficacy and tolerability with their respec-
tive pharmacological profile (Table 3). 
Moreover, for some of these compounds, their metabolic 
pattern appears to be essential to explain their activities. As an 
example, mesulergine seems to exhibit a biphasic action on the 
DA turnover: after an initial receptor blockade, an agonistic 
effect was observed only 4 hours later (Flueckiger et al, 1979; 
Enz, 1981, 1982; Ringwald et al., 1982). However, this effect 
was mainly observed after subcutaneous administration (Fig. 
2). When the compound is given orally, the initial activation of 
DA turnover is much reduced (Enz et al., 1983). Such a differ-
ence can be explained by the metabolic pattern of this agent, 
which is actively and rapidly transformed into various metabolites. 
Among these metabolites, the major two (CH 29-717 and 204-079) 
exhibit potent dopaminergic properties. In addition to the meta-
bolic pattern, it is important to compare the pharmacokinetics 
of these agents within the plasma and the striatum as the target 
organ. 
The claimed advantage of dopaminergic drugs over L-Dopa 
was the longer half-life inducing a longer clinical benefit. How-
ever such a statement was referring only to the plasma kinetic 
properties, not taking into account the drug kinetics within the 
target organ, i.e. the striatum. With mesulergine, however, this 
last effect was investigated. After an oral dose of 10 mg/kg (Fig. 
3), there is in the striatum a rapid appearance of the active 
metabolites with a concomitant decrease of the parent drug 
(Enz etal . , 1983). 
Another controversial aspect of ergot pharmacology con-
cerns the concept of DA-receptors (see Seeman P. and Kebabian 
J.) 
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Comparat ive pharmacokinetics of mesulergine 
and metabol i tes (Enz et ai.. 1983) 
log rig/ml 
plasma 
/ -
1-
f l -
1_ 
f ^ f I 
/ 
I 
^ 
I I I I 
1.50-
log ng/g 
striatum 
0.50-
Hours after p.o. applic. 10 mg/kg 
- • CU 32-085 • • CH 29-717 • — — • 204-079 
Figure 3 — Comparative pharmacokinetics of Mesulergine and metabolites 
in plasma and striatum, (from Enz et at., 1983 with permission). 
In animal models, the central dopaminergic activities of 
bromocriptine were investigated mainly in acute conditions. 
Few data are available upon the effects observed during chronic 
administration. Recently such a chronic treatment was per-
formed (Vigouret et al., 1983) in the stereotyped behaviour 
model in intact rats as well as in the Ungerstedt model. 
As reviewed in Table 4, behavioural dopaminergic stereoty-
pies were generally observed with acute doses over 30 mg/kg 
given orally. In chronic conditions, pronounced stereotypies 
appeared after 5 weeks at a daily dose of 12 mg/kg with a 
concomitant significant decrease of DOPAC level within the 
striatum. The DA turnover was not significantly influenced in 
acute stimulation. These observations indicate the appearance 
of a behavioural and biochemical hypersensitivity to bromocriptine 
during the chronic use of oral doses inactive when given acutely. 
Moreover the unilateral lesioning of nigrostriatal pathways by 
local injection of 6-OH-DA leads to a supersensitivity of DA 
receptors within the striatum. Dopaminomimetic agents such 
as apomorphine or bromocriptine induce a contralateral turn-
ing behaviour by stimulation of the "denervated" DA receptors. 
Such behaviour was observed for acute doses of bromocriptine 
over 9 mg/kg, but reproducible effects were obtained with 
20 mg/kg. A comparable turning pattern was recorded in chronic 
condition after the third week at a daily dose of 6 mg/kg (Table 
5). The latency of the turning behaviour was about 2 hours, 
followed by a longer period of dopaminergic stimulation (more 
than 7 hours). 
The comparison of the effects obtained after either acute or 
chronic administration points out the complex pharmacology 
of dopaminergic agents. A repeated administration seems to 
induce a functional supersensitivity probably related to post-
synaptic DA receptors. However the participation of other DA 
receptors cannot be excluded, i.e. presynaptic DA receptors. 
The biochemical mechanisms underlying such dynamic aspects 
of receptor stimulation are still unknown. However the clinical 
implication of these results appears to be essential especially 
forthe initiation of dopaminergic agents in parkinsonian patients. 
The titration period should be carefully built-up before the 
onset of an optimal effect. The therapeutic response seems to 
require a certain delay, depending for each patient upon the 
dynamic situation of his DA receptor systems. Moreover the 
antiparkinsonian effect can increase over time without addi-
tional increase in the daily regimen after the appearance of the 
first signs of clinical improvement. 
These pharmocological elements emphasize the complexity 
of the DA receptor concept. From biochemical in vitro tests, it 
seems difficult to extrapolate to in vivo conditions related to 
Parkinson's disease. Our understanding of the dynamics of 
receptors is yet quite uncertain, as is that of the compensatory 
mechanisms which probably take place during the natural pro-
gression of the degenerative process. 
Table 4: Effects of acute and chronic administration of bromocriptine 
in stereotyped behaviour (from Vigouret, unpublished) 
Acute Dose 
Control 
Dose 
mg/kg p.o. 
3 
10 
30 
Dose 
mg/kg p.o./Day Week 
Score 
(N = 6) 
0.6 + 0.7 
0.6 + 0.8 
7.3 + 1.2(p<0.05) 
0.5+0.4 
Score 
(N = 6) 
Chronic Dose 1 
3 
6 
9 
12 
1 
2 
3 
4 
5 
0.3 + 0.3 
0.3 + 0.2 
0.4 + 0.2 
0.8 + 0.3 
13.4 + 1.3(p<0.01) 
Table 5: Effects of acute and chronic administration of bromocriptine 
in Ungerstedt model (from Vigouret, unpublished) 
Dose 
mg/kg p.o. Week 
Total Number of 
Contralat. Rotations 
(7h.) 
Acute Dose 
(N = 6) 
1 
3 
6 
9 
20 
0 
0 
0 
152 + 21 
1600 + 185 
Chronic Dose 
(N=12) 
24 + 14 
15 + 57 
1093 + 200 
1080 + 320 
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As an example, the balanced activation of 2 types of DA 
receptors (pre- and post-synaptic) seems to be essential for an 
adequate integration of striatal functions. The mechanisms under-
lying this balance are still unknown within normal physiological 
conditions as well as during the natural course of the degenera-
tive process underlying Parkinson's disease (Flueckiger and 
Vigouret, 1981). 
Conclusions 
In recent years, the dopaminergic properties of ergot com-
pounds have attracted much attention whereas other aspects of 
their receptor pharmacology still remain unclear. Moreover 
small differences within their chemical structure may produce 
qualitative changes in their profile of actions. Particularly inter-
esting is the possible relationship between in vivo and in vitro 
activities to explain such a multiplicity of profiles. Ergot deriva-
tives have had an important impact on our understanding of 
central dopaminergic functions and have served as useful tools 
for pharmacological research. However, the DA receptor con-
cept is not yet satisfactory, especially when confronted to its 
clinical implications. The clinical contribution of dopamino-
mimetic ergots is essential but far from being completely 
understood. New approaches, perhaps more specific ones, are 
required to provide ample and clear information to optimize 
their pharmacodynamic properties. According to their mecha-
nism of action, they allow continued treatment for parkinso-
nian patients who become resistant to L-Dopa or no longer 
tolerate it because of adverse reactions, such as dyskinesia or 
"on-off' phenomenon (Lieberman et al., 1976; Calne et al., 
1978; Ringwald, 1982). 
In newly diagnosed patients, dopaminergic agents such as 
bromocriptine or mesulergine may represent an alternative to 
chronic L-Dopa treatment. According to preliminary results 
(Lees et al., 1978; Rascol et al., 1982; Hirt et al., 1983) these 
compounds given as monotherapy had a low potential for pro-
ducing dyskinesia or "on-off phenomenon over at least 5 
years. The extension of this experience overtime is essential to 
provide clear evidence of the therapeutical potential of ergots 
in the chronic management of parkinsonism, avoiding the dis-
abling problems associated with L-Dopa. 
Despite the real improvement in the quality of life of parkinso-
nian patients with L-Dopa and/or dopaminergic agents, the 
natural course of disease remains unchanged. In this respect no 
real progress was made since the optimistic conclusion of Par-
kinson (1817) in his original essay: 
"There appears to be sufficient reason for hoping that some 
remedial process may ere long be discovered by which at least 
the progress of the disease may be stopped". 
Recently new prospects were offered to pharmacologists 
with the recognition of chemically induced parkinsonism in 
young addicts (Davis et al., 1979; Langston et al., 1983; Burns 
et al., 1983). The development of a more accurate model for 
parkinsonism in rhesus monkeys receiving NMPTP (N-methyl-
4-phenyl-l,2,3,6-tetrahydropyridine) could probably improve 
our understanding of the basic pathological mechanism of par-
kinsonian degeneration. This model, if it truly reproduces the 
neurological syndrome, could be a useful tool in the selection of 
new antiparkinsonian drugs among ergot derivatives. This is 
the future challenge offered to neuropharmacology. 
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